{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:28:32Z","timestamp":1784914112759,"version":"3.55.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>There are 7 known serotypes of botulinum neurotoxins (A through G). Currently, commercially available toxins are those in serotypes A and B. This paper will discuss new toxins on the horizon, developments in prolonging and shortening the duration of outcomes, and novel therapeutic indications on the horizon.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To provide insight into new toxins and new therapeutic modalities surrounding toxins on the horizon.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>The authors have reviewed the relevant literature and shared their insights and opinions as to future developments in toxin research and potential clinical applications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Botulinum neurotoxin type E's faster onset and shorter duration of effect represent true clinical differentiators. Future development of botulinum neurotoxin type E for aesthetic and therapeutic uses will be in areas where fast onset and short duration of effect are desirable. Current challenges with neuromodulators include the need for frequent treatments and lack of reversal agents. Agents to address both challenges and novel indications, including inhibition of melanogenesis, are being developed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004346","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:54:30Z","timestamp":1724889270000},"page":"S112-S116","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["New and Future Developments in Neurotoxins"],"prefix":"10.1097","volume":"50","author":[{"given":"Steve","family":"Yoelin","sequence":"first","affiliation":[{"name":"Medical Associates, Inc., Newport Beach, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Hooper","sequence":"additional","affiliation":[{"name":"Audubon Dermatology, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"R1-20241006","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/der2.155","article-title":"Botulinum toxin type E: a review","volume":"3","author":"Lebowitz","year":"2022","journal-title":"Dermatol Rev"},{"key":"R2-20241006","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jmb.2008.12.027","article-title":"Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation","volume":"386","author":"Kumaran","year":"2009","journal-title":"J Mol Biol"},{"key":"R3-20241006","first-page":"179","article-title":"Persistence of Botulinum neurotoxin inactivation of nerve function","volume":"364","author":"Shoemaker","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"R4-20241006","doi-asserted-by":"crossref","first-page":"E5158","DOI":"10.1073\/pnas.1621076114","article-title":"Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication","volume":"114","author":"Tsai","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-20241006","first-page":"16993-7002","article-title":"Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics","volume":"283","author":"Wang","year":"2008","journal-title":"J Biol Chem"},{"key":"R6-20241006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.febslet.2010.11.045","article-title":"Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1","volume":"585","author":"Pier","year":"2011","journal-title":"FEBS Lett"},{"key":"R7-20241006","doi-asserted-by":"crossref","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","article-title":"Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study","volume":"142","author":"Yoelin","year":"2018","journal-title":"Plast Reconstr Surg"},{"key":"R9-20241006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/DSS.0000000000001360","article-title":"The cellular response of keloids and hypertrophic scars to botulinum toxin A: a comprehensive literature review","volume":"44","author":"Austin","year":"2018","journal-title":"Dermatol Surg"},{"key":"R10-20241006","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1097\/SAP.0000000000000268","article-title":"Botulinum toxin type A inhibits \u03b1-smooth muscle actin and myosin ii expression in fibroblasts derived from scar contracture","volume":"77","author":"Chen","year":"2016","journal-title":"Ann Plast Surg"},{"key":"R11-20241006","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0748806818776156","article-title":"Botulinum toxin-A and scar reduction: a review","volume":"35","author":"Honeybrook","year":"2018","journal-title":"Am J Cosmet Surg"},{"key":"R12-20241006","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1524-4725.2008.34407.x","article-title":"Use of intraoperative botulinum toxin in facial reconstruction","volume":"35","author":"Flynn","year":"2009","journal-title":"Dermatol Surg"},{"key":"R14-20241006","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jaad.2023.08.072","article-title":"Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: a randomized controlled trial","volume":"89","author":"Alam","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R15-20241006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam","year":"2010","journal-title":"Indian J Dermatol"},{"key":"R17-20241006","first-page":"295","article-title":"Dermal fillers in aesthetics: an overview of adverse events and treatment approaches","volume":"6","author":"Funt","year":"2013","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R18-20241006","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1067\/mjd.2000.105567","article-title":"Pharmacology of botulinum toxin","volume":"43","author":"Huang","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R19-20241006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.11138\/FNeur\/2018.33.1.007","article-title":"Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal","volume":"33","author":"Ferrari","year":"2018","journal-title":"Funct Neurol"},{"key":"R21-20241006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0928-4257(01)00086-9","article-title":"Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission","volume":"96","author":"Meunier","year":"2002","journal-title":"J Physiol Paris"},{"key":"R22-20241006","doi-asserted-by":"crossref","first-page":"1226194","DOI":"10.3389\/fncel.2023.1226194","article-title":"Neuromuscular recovery from botulism involves multiple forms of compensatory plasticity","volume":"17","author":"Machamer","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"R23-20241006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-017-00064-y","article-title":"Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors","volume":"8","author":"Tao","year":"2017","journal-title":"Nat Commun"},{"key":"R24-20241006","doi-asserted-by":"crossref","first-page":"30429","DOI":"10.1038\/srep30429","article-title":"Pre-clinical study of a novel recombinant botulinum neurotoxin derivative engineered for improved safety","volume":"6","author":"Vazquez-Cintron","year":"2016","journal-title":"Sci Rep"},{"key":"R25-20241006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17460441.2017.1303476","article-title":"Challenges in searching for therapeutics against botulinum neurotoxins","volume":"12","author":"Pirazzini","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"R30-20241006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/20501684231197717","article-title":"Complications of toxins and fillers in facial aesthetics","volume":"12","author":"Samizadeh","year":"2023","journal-title":"Prim Dent J"},{"key":"R32-20241006","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"key":"R26-20241006","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/cc12880","article-title":"3,4-Diaminopyridine may improve neuromuscular block during botulism","volume":"17","author":"Friggeri","year":"2013","journal-title":"Crit Care"},{"key":"R27-20241006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10020-022-00487-4","article-title":"Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine","volume":"28","author":"Machamer","year":"2022","journal-title":"Mol Med"},{"key":"R28-20241006","doi-asserted-by":"crossref","first-page":"15862","DOI":"10.1038\/s41598-017-16064-3","article-title":"Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A","volume":"7","author":"Beske","year":"2017","journal-title":"Sci Rep"},{"key":"R29-20241006","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1016\/j.bmc.2011.09.019","article-title":"Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization","volume":"19","author":"Zakhari","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"R33-20241006","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/264787a0","article-title":"Effect of botulinum toxin on trophic regulation of acetylcholine receptors","volume":"264","author":"Pestronk","year":"1976","journal-title":"Nature"},{"key":"R34-20241006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpeds.2017.11.013","article-title":"Pyridostigmine for the reversal of severe adverse reactions to botulinum toxin in children","volume":"194","author":"Boerner","year":"2018","journal-title":"J Pediatr"},{"key":"R35-20241006","first-page":"CD006986","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","volume":"2014","author":"Mehndiratta","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R36-20241006","first-page":"23","article-title":"Spotlight On: ReViVox","volume":"11","year":"2023","journal-title":"Aesthetics J"},{"key":"R37-20241006","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2013.156","article-title":"Syntaxin-3 is required for melanosomal localization of Tyrp1 in melanocytes","volume":"133","author":"Yatsu","year":"2013","journal-title":"J Invest Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T03:15:19Z","timestamp":1728184519000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":32,"journal-issue":{"issue":"9S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004346","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}